Company news

Zealand Pharma A/s (OMXCOP:ZEAL) news

Zealand Pharma A/s news releases on 6ix. Latest, Oct 1, 2026: Zealand Pharma A/S : announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight…

Zealand Pharma A/s (OMXCOP:ZEAL) news

Press releases & updates

Zealand Pharma A/S : announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology

Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)

Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)

Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome

Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)

Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)

Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)

Zealand Pharma – Notification of holding of treasury shares

Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)

Zealand Pharma - Transactions related to share buy-back program

Zealand Pharma - Transactions related to share buy-back program (week 33, 2026)

Zealand Pharma Announces Financial Results for the First Half of 2026

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide

Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)

Zealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial results

Zealand Pharma - Transactions related to share buy-back program (week 31, 2026)

Zealand Pharma - Transactions related to share buy-back program (week 30, 2026)

Zealand Pharma: Transactions related to share buy-back program (week 29, 2026)

Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)

Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)

Total number of shares and voting rights in Zealand Pharma as of June 30, 2026

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)

Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)

Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)

Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis

Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference

Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)

Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions

Zealand Pharma - Transactions related to share buy-back program (week 21, 2026)

Resolutions from Zealand Pharma's Extraordinary General Meeting 2026

Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)

Zealand Pharma A/S : Q1 Financial Results / Interim Report First Quarter 2026

Zealand Pharma A/S : Interim Report for Q1 2026

Zealand Pharma Announces Financial Results for the First Three Months of 2026

Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program

Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026

Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results

Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management

Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026

Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations

Total number of shares and voting rights in Zealand Pharma as of March 31, 2026

Resolutions from Zealand Pharma's Annual General Meeting 2026

Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation

Zealand Pharma increases its share capital as a result of the exercise of employee warrants